Abstract Background Enfortumab vedotin plus pembrolizumab (EVP) is first-line standard therapy for locally advanced or metastatic urothelial carcinoma (LA/mUC), but real-world pneumonitis incidence and predictors remain poorly characterized. Material and methods We conducted a retrospective cohort study of patients wit...
Luis Angel Diaz Tejada, Fabiana Alexandra Príncipe Osorio, A. Attia et al.· The Oncologist· 0 citations
It is suggested that treatment-emergent skin toxic effects may serve as an early clinical marker of treatment benefit in patients receiving first-line enfortumab vedotin plus pembrolizumab and warrant prospective validation.
Zachariah Thomas, Cindy Y. Jiang, Patrick Speck et al.· JAMA Network Open· 0 citations
Field surveys in Jabal al Druze, southern Syria, rediscovered Salvia drusica and Centaurea trachonitica and provided the first modern population-level documentation of both species. We provide updated information on distribution, population size, morphology, habitat, associated flora and threats, together with prelimin...
O. Alhalabi, Ramy Maalouf, E. Véla· Phytotaxa· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.